Metformin has been a cornerstone in managing type 2 diabetes primarily known for its effects on the liver and gut. For over 60 years, it has been prescribed to help control blood sugar levels, but recent developments are reshaping our understanding of its broader implications, particularly concerning brain health.
New research indicates that metformin operates in the brain by shutting down a protein called Rap1 in the ventromedial hypothalamus. This discovery has led experts to reconsider the drug’s role, as it activates SF1 neurons when introduced into the brain. According to Makoto Fukuda, a leading researcher in the field, “This discovery changes how we think about metformin. It’s not just working in the liver or the gut, it’s also acting in the brain.”
Moreover, metformin is recognized for its potential to slow brain aging. A 2025 study revealed that individuals using metformin had a 30% lower risk of dying before age 90 compared to those taking sulfonylurea, underscoring its gerotherapeutic properties. Fukuda elaborated, “We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels.” This suggests that metformin’s efficacy in the brain could be significant even at lower dosages.
In addition to its diabetes management capabilities, metformin has been shown to reduce wear and tear in the brain and may help mitigate the risks associated with long COVID. However, it is important to note that approximately 75% of those taking metformin experience gastrointestinal problems, which can complicate its use.
As these findings continue to emerge, the medical community is keenly observing how this could influence treatment protocols for both diabetes and cognitive health. The implications of metformin’s action in the brain could lead to new therapeutic strategies aimed at enhancing brain function and longevity.
What remains to be seen is how these insights will be integrated into clinical practice and whether further research will confirm these initial findings. Details remain unconfirmed, but the potential for metformin to serve as a dual-purpose medication is an exciting prospect for both patients and healthcare providers alike.
